Ilieva Mirolyuba, Uchida Shizuka
Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Ann Transl Med. 2022 Jul;10(13):753. doi: 10.21037/atm-22-1074.
The recent emergence of epitranscriptomics provides an avenue for identifying RNA modifications implicated in the pathophysiology of human disease. To date, over 170 RNA modifications have been identified; these modifications are important because they can affect the fate of RNAs, including their decay, maturation, splicing, stability, and translational efficiency. Although RNA modifications have been reported in many tissues and disease contexts, detailed functional studies in the heart and cardiovascular disease are only beginning to be reported.
The search for relevant articles related to epitranscriptomics was conducted by focusing on the cardiovascular system and disease in the PubMed database.
We summarize the recent findings of three epitranscriptomic marks-N6-methyladenosine (mA), adenosine to inosine (A-to-I) RNA editing, and 5-methylcytosine (mC) as other epitranscriptomic marks are not studied extensively in the cardiovascular system and disease.
In this narrative review, the current status of cardiac epitranscriptomics is summarized to raise the awareness of this important field of study.
表观转录组学的近期出现为鉴定与人类疾病病理生理学相关的RNA修饰提供了一条途径。迄今为止，已鉴定出超过170种RNA修饰；这些修饰很重要，因为它们会影响RNA的命运，包括其降解、成熟、剪接、稳定性和翻译效率。尽管RNA修饰已在许多组织和疾病背景中被报道，但在心脏和心血管疾病方面的详细功能研究才刚刚开始被报道。
通过聚焦于PubMed数据库中的心血管系统和疾病来搜索与表观转录组学相关的文章。
我们总结了三种表观转录组学标记——N6-甲基腺苷（m⁶A）、腺苷到肌苷（A-to-I）RNA编辑和5-甲基胞嘧啶（m⁵C）的近期发现，因为其他表观转录组学标记在心血管系统和疾病中未得到广泛研究。
在这篇叙述性综述中，总结了心脏表观转录组学的现状，以提高对这一重要研究领域的认识。
